Trinity Biotech (TRIB) Income from Discontinued Operations (2021 - 2024)

Trinity Biotech has disclosed Income from Discontinued Operations across 4 years of filings, most recently posting -$573000.0 for Q4 2024.

• In Q4 2024, Income from Discontinued Operations fell 19000.0% year-over-year to -$573000.0; the TTM figure through Dec 2024 stood at $11.8 million (down 8.32% YoY), while the FY2024 annual figure was -$573000.0, down 104.46% from the prior year.
• Income from Discontinued Operations came in at -$573000.0 for Q4 2024 at Trinity Biotech, down from -$3000.0 in the prior quarter.
• In the past five years, Income from Discontinued Operations ranged from a high of $12.4 million in Q2 2023 to a low of -$573000.0 in Q4 2024.
• Average Income from Discontinued Operations over 4 years is $1.3 million, with a median of $336000.0 recorded in 2022.
• Year-over-year, Income from Discontinued Operations soared 3696.55% in 2022 and tumbled 19000.0% in 2024.
• Over 4 years, Income from Discontinued Operations stood at -$25000.0 in 2021, then jumped by 1444.0% to $336000.0 in 2022, then sank by 100.89% to -$3000.0 in 2023, then plunged by 19000.0% to -$573000.0 in 2024.
• Per Business Quant data, the three most recent Income from Discontinued Operations figures were -$573000.0 in Q4 2024, -$3000.0 in Q4 2023, and -$1000.0 in Q3 2023.